CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Carfilzomib--dexamethasone vs bortezomib--dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
Authors
WJ Chng Goldschmidt, H Dimopoulos, MA Moreau, P Joshua, D Palumbo, A Facon, T Ludwig, H Pour, Luděk Niesvizky, R others
Publication date
1 January 2017
Publisher
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:2954000
Last time updated on 10/02/2023
